News | May 03, 2024
Novartis to acquire Mariana Oncology for upfront US$ 1 billion
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
Acquisition encompasses a portfolio of RLT programs across a range of solid tumor indications
If approved, the Opdivo-based regimen would be the first immunotherapy-chemotherapy combination approved for this patient population in the EU
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
Pemetrexed Injection is used as a drug, in the treatment of non-small cell lung cancer in combination with other chemotherapy agents
First and only immunotherapy to demonstrate survival benefit in this setting in a global Phase III trial
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Application based on results from the TROPION-Breast01 Phase III trial
The FDA assigned a Prescription Drug User Fee Act (PDUFA) goal date of June 21, 2024
Combination shows consistent benefit across prespecified post-progression outcomes
Versavo is the first Dr. Reddy's biosimilar product to be approved and launched in the UK
Subscribe To Our Newsletter & Stay Updated
